Article ; Online: Donafenib treatment for hepatocellular carcinoma: A case report.
2021 Volume 100, Issue 25, Page(s) e26373
Abstract: Rationale: Hepatocellular carcinoma (HCC) is the most common liver cancer. The efficacy of the present treatment is disappointing, and the prognosis is poor. Donafenib, a novel multikinase inhibitor, is a new deuterated derivative of sorafenib. It can ... ...
Abstract | Rationale: Hepatocellular carcinoma (HCC) is the most common liver cancer. The efficacy of the present treatment is disappointing, and the prognosis is poor. Donafenib, a novel multikinase inhibitor, is a new deuterated derivative of sorafenib. It can improve overall survival in patients with advanced HCC, with a favorable safety and tolerability profile over sorafenib. Patient concerns: Here, we report the case of a 51-year-old male patient who presented with experienced epigastric discomfort for the prior several days. He had a history of untreated chronic hepatitis B virus infection for >29 years and no other underlying diseases. Based on further investigations, he was diagnosed with advanced HCC and refused surgery. Diagnosis: Based on the patient's performance status, tumor status assessed by computed tomography, liver function, and percutaneous liver biopsy, he was diagnosed with advanced HCC Barcelona Clinic Liver Cancer Stage C. Interventions: The patient was administered a 200-mg oral dose of donafenib twice-daily. Outcomes: The patient was followed-up from the time of diagnosis. He received donafenib for 31 months, and the progression-free survival time was 31 months (from May 2017 to December 2019); the overall survival time was not reached. The patient reported little abdominal distension with no other obvious discomfort while taking the medication. Lesson: Donafenib showed good efficacy for the treatment of advanced HCC, with mild side effects. Deuterium-containing drugs seem to be a promising avenue for medical innovation. |
---|---|
MeSH term(s) | Biopsy ; Carcinoma, Hepatocellular/diagnosis ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/therapy ; Carcinoma, Hepatocellular/virology ; Disease Progression ; Drug Therapy, Combination/methods ; Guanine/analogs & derivatives ; Guanine/therapeutic use ; Hepatectomy ; Hepatitis B, Chronic/pathology ; Hepatitis B, Chronic/therapy ; Hepatitis B, Chronic/virology ; Humans ; Liver/diagnostic imaging ; Liver/pathology ; Liver/surgery ; Liver Neoplasms/diagnosis ; Liver Neoplasms/pathology ; Liver Neoplasms/therapy ; Liver Neoplasms/virology ; Male ; Middle Aged ; Neoadjuvant Therapy/methods ; Pyridines/therapeutic use ; Tomography, X-Ray Computed ; Treatment Outcome |
Chemical Substances | Pyridines ; donafenib (41XGO0VS1U) ; entecavir (5968Y6H45M) ; Guanine (5Z93L87A1R) |
Language | English |
Publishing date | 2021-06-23 |
Publishing country | United States |
Document type | Case Reports ; Journal Article |
ZDB-ID | 80184-7 |
ISSN | 1536-5964 ; 0025-7974 |
ISSN (online) | 1536-5964 |
ISSN | 0025-7974 |
DOI | 10.1097/MD.0000000000026373 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Ua VI Zs.171: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.